SciELO - Scientific Electronic Library Online

 
vol.80 issue4Central venous-to-arterial CO2 difference as a biomarker of outcome in children who underwent surgery for congenital heart diseaseMassive pleural empyema secondary to amoebic liver abscess in a child author indexsubject indexsearch form
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Boletín médico del Hospital Infantil de México

Print version ISSN 1665-1146

Abstract

MARRIAGA-NUNEZ, Bibiana et al. Immunoglobulin-resistant Kawasaki disease. Bol. Med. Hosp. Infant. Mex. [online]. 2023, vol.80, n.4, pp.260-264.  Epub Oct 09, 2023. ISSN 1665-1146.  https://doi.org/10.24875/bmhim.23000078.

Background:

Kawasaki disease is a systemic vasculitis that affects small and medium-sized vessels, primarily the coronary arteries. First-line treatment includes intravenous immunoglobulin (IVIG) and acetylsalicylic acid; however, 20% do not respond adequately despite treatment. We describe a case treated with etanercept after initial IVIG failure, showing a good response.

Case report:

A 5-year-old female was diagnosed with classic Kawasaki disease. Echocardiography and angiotomography revealed giant and fusiform aneurysms in the coronary arteries. A first dose of IVIG therapy was administered without improvement; after the second dose, the fever persisted, so etanercept was administered, and the fever subsided. There were no new lesions in medium-caliber vessels and the previously identified coronary lesions did not progress.

Conclusions:

The use of etanercept in Kawasaki disease has demonstrated a clinically favorable response. Controlled clinical trials of this drug are needed to establish it as a formal therapy in cases of initial IVIG failure.

Keywords : Kawasaki disease; Therapeutic failure; TNFα; Etanercept; Case report.

        · abstract in Spanish     · text in English     · English ( pdf )